Fresh Tracks Therapeutics Fresh Tracks Therapeutics Home
  • Company
    • Vision
    • Values
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partner With Us
    • Join Us
  • Scientific Innovations
  • Pipeline
    • Overview
    • FRTX-02
    • FRTX-10
    • Next-Generation Kinase Inhibitors
    • FRTX-03
  • Investor Relations
Main Menu
Contact Us
Investor Relations

News

Investors

Investors

  • Overview
  • News
  • Events
  • Presentations
  • Governance
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
Sep 01, 2021 7:00am EDT

Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases

Aug 16, 2021 8:00am EDT

Brickell Biotech Announces Final Patient Completed Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Aug 12, 2021 4:01pm EDT

Brickell Biotech Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Jul 29, 2021 8:00am EDT

Brickell Biotech to Report Second Quarter 2021 Financial Results and Provide a Corporate Update on August 12, 2021

Jul 22, 2021 4:05pm EDT

Brickell Biotech Announces Closing of $8.05 Million Bought Deal Offering of Common Stock, Including Full Exercise of the Underwriter’s Option to Purchase Additional Shares

Jul 19, 2021 10:44pm EDT

Brickell Biotech Increases Previously Announced Bought Deal Offering of Common Stock to $7.0 Million

Jul 19, 2021 5:25pm EDT

Brickell Biotech Announces $5.0 Million Bought Deal Offering of Common Stock

Jul 06, 2021 8:00am EDT

Brickell Biotech to Participate at William Blair’s Biotech Focus Conference 2021

Jun 29, 2021 4:05pm EDT

Brickell Biotech Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Jun 24, 2021 8:00am EDT

Brickell Biotech Announces Initiation of a Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by its Development Partner, Kaken Pharmaceutical in Japan

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Next Pagearrow_forward
  • Email Alerts
  • RSS News Feed

Company

  • Vision
  • Values
  • Leadership
  • Partner With Us
  • Join Us

Discover

  • Scientific Innovations
  • Pipeline
  • Investor Relations
  • News
  • Contact Us

Follow Us

  • LinkedIn
  • Twitter
  • Instagram
  • Facebook
  • Compliance
  • Terms of Use
  • Privacy Policy
  • Accessibility
©2023 Fresh Tracks Therapeutics, Inc.

We use first- and third-party cookies to obtain statistical information to personalize our website and provide you with a better experience. If you continue without changing your settings, this demonstrates your consent to receive all cookies or other tracking technologies on the FRTX website for the purposes described in our Privacy Policy. Please know that you can change your cookie settings at any time in your browser settings.

Close